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Introduction
• About 1 in 200 babies are born with 
congenital Cytomegalovirus (cCMV) in the 
US and 90% of infections are asymptomatic1
• Infections can result in permanent sequelae 
such as sensorineural hearing loss, vision 
impairment, and developmental disabilities
• More than 50% of symptomatic infections 
result in permanent sequelae2
• Studies using administrative databases have 
used CMV diagnostic codes assigned within 
the first 90 days of life to identify cCMV 
infections and found a prevalence of 1-4 per 
10,000 births3
• ICD-9-CM and ICD-10-CM diagnostic codes 
are used primarily for billing or 
administrative purposes, and their 
sensitivity in identifying cCMV infections has 
not been evaluated
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Objectives
1. To evaluate the sensitivity of diagnostic 
codes in identifying infants with laboratory-
confirmed cCMV infections at healthcare 
facilities that provide CMV lab data 
2. To determine the prevalence of laboratory-
confirmed cCMV 
3. To investigate conditions associated with 
cCMV using diagnostic codes
Patient Population: Infants with at least one encounter in the first 21 or 90 days of 
life at a facility that provided CMV data to Cerner Health Facts Database from 2010-
2017
Laboratory-confirmed cCMV infected infants: Infants with a positive CMV laboratory 
test meeting inclusion criteria in the first 21 or 90 days of life
Diagnostic Codes (ICD-9-CM and ICD-10-CM) corresponding to CMV and CMV-
related conditions were investigated among the laboratory-confirmed cCMV 
infected infants. A restriction of 21 or 90 days was applied for CMV diagnostic codes 
to account for delay in assignment and 90 days for all other diagnostic codes.
7,908,711 infants with encounters in first 90 days of 
life (349 hospitals)
1,072 infants had a positive CMV test 
838 infants had a test that met cCMV laboratory 
criteria
668 infants were within 21 days at time of test
Methods
Prevalence of Laboratory-
confirmed cCMV infected 
infants:
Using 90-day cut-offs for 
tests/encounters: 
1.1 cases per 10,000 infants
Using 21-day cut-offs for 
tests/encounters: 
0.9 cases per 10,000 infants
Inclusion Criteria: PCR, DFA, or culture from saliva, urine, respiratory secretion, CSF, 











CMV test in first 21 days ≤21 days 668 69 10.3 (8.0, 12.6)
CMV test in first 21 days ≤90 days 668 74 11.1 (8.7, 13.5)
CMV test in first 90 days ≤90 days 838 107 12.8 (10.5, 15.0)
The sensitivity of CMV diagnostic codes among laboratory-confirmed cCMV infected 
infants using 21- and 90-day cut-offs for CMV tests and diagnostic code assignment
• About 1 in 10 infants with laboratory-confirmed 
cCMV also had CMV diagnostic codes in this 
population of infants at 349 US hospitals
• The sensitivity of CMV diagnostic codes did not 
substantially change with different age 
restrictions
• The administrative prevalence of cCMV was like 
other studies, but laboratory results were used 
instead of diagnostic codes to identify infants
• Low birth weight (31%), jaundice (26%), and 
thrombocytopenia (15%) were the most 
common cCMV associated conditions in those 
less than 21 days at time of test. Microcephaly 
was present in about 4% and hearing loss in 6%.
• Most laboratory-confirmed infants (21 days) 
were identified through culture alone (77%) 
and only 10% had a positive PCR test
• Infants in the Northeast represented 20% of the 
total patient population and 55% of the 
laboratory-confirmed cCMV infected population 
which indicates missing laboratory data. 
Conclusions
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